Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary extracted from

  • Infante, E.; Aguilar, L.D.; Gicquel, B.; Pando, R.H.
    Immunogenicity and protective efficacy of the Mycobacterium tuberculosis fadD26 mutant (2005), Clin. Exp. Immunol., 141, 21-28 .
    View publication on PubMedView publication on EuropePMC

Application

EC Number Application Comment Organism
6.2.1.59 medicine a FadD26 mutant has impaired synthesis of phthiocerol dimycocerosates and is attenuated in BALB/c mice. The FadD26 mutant induces less pneumonia and larger delayed-type hypersensitivity reactions. It induces lower but progressive production of interferon-gamma, interleukin-4 and tumour necrosis factor-alpha. Used as a subcutaneous vaccine, the mutant induces a higher level of protection than does strain Bacille Calmette-Guérin (BCG). There is less tissue damage (pneumonia) and lower colony-forming units in the mice vaccinated with the FadD26 mutant compared to the findings in mice vaccinated with BCG Mycobacterium tuberculosis

Organism

EC Number Organism UniProt Comment Textmining
6.2.1.59 Mycobacterium tuberculosis
-
-
-
6.2.1.59 Mycobacterium tuberculosis MT103
-
-
-

Synonyms

EC Number Synonyms Comment Organism
6.2.1.59 FadD26
-
 Mycobacterium tuberculosis

General Information

EC Number General Information Comment Organism
6.2.1.59 physiological function a FadD26 mutant has impaired synthesis of phthiocerol dimycocerosates and is attenuated in BALB/c mice. The FadD26 mutant induces less pneumonia and larger delayed-type hypersensitivity reactions. It induces lower but progressive production of interferon-gamma, interleukin-4 and tumour necrosis factor-alpha. Used as a subcutaneous vaccine, the mutant induces a higher level of protection than does strain Bacille Calmette-Guérin (BCG). There is less tissue damage (pneumonia) and lower colony-forming units in the mice vaccinated with the FadD26 mutant compared to the findings in mice vaccinated with BCG Mycobacterium tuberculosis